Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than general financial performance.
Material Changes
Following a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan (notionally held in GSK Ordinary share ADRs), the Plan Administrators notified the registrant of an increase in the notional allocation of Ordinary share ADRs on April 30, 2009. The transaction price was $30.76 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- The filing reports an increase in notional ADR allocations for specific directors and executives within the US Retirement Savings Plan.
- The transaction date was April 30, 2009, with a price of $30.76 per ADR.
- Individuals notified include Mr. E J Gray, Mr. W C Louv, Dr. D Pulman, Dr. M M Slaoui, and Mrs. C Bruck Slaoui.
- No financial performance data is included in this specific report.